BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buenaventura T, Bitsi S, Laughlin WE, Burgoyne T, Lyu Z, Oqua AI, Norman H, McGlone ER, Klymchenko AS, Corrêa IR Jr, Walker A, Inoue A, Hanyaloglu A, Grimes J, Koszegi Z, Calebiro D, Rutter GA, Bloom SR, Jones B, Tomas A. Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells. PLoS Biol 2019;17:e3000097. [PMID: 31430273 DOI: 10.1371/journal.pbio.3000097] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
Number Citing Articles
1 Walker AR, Larsen CB, Kundu S, Stavrinidis C, Kim SH, Inoue A, Woodward DF, Lee YS, Migale R, MacIntyre DA, Terzidou V, Fanelli F, Khanjani S, Bennett PR, Hanyaloglu AC. Functional rewiring of G protein-coupled receptor signaling in human labor. Cell Rep 2022;40:111318. [PMID: 36070698 DOI: 10.1016/j.celrep.2022.111318] [Reference Citation Analysis]
2 Manchanda Y, Bitsi S, Chen S, Broichhagen J, de la Serna JB, Jones B, Tomas A. An examination of the divergent spatiotemporal signaling of GLP-1R versus GIPR in pancreatic beta cells.. [DOI: 10.1101/2022.08.17.504231] [Reference Citation Analysis]
3 McGlone ER, Ansell TB, Dunsterville C, Song W, Carling D, Tomas A, Bloom SR, Sansom MSP, Tan T, Jones B. Hepatocyte cholesterol content modulates glucagon receptor signalling. Mol Metab 2022;:101530. [PMID: 35718339 DOI: 10.1016/j.molmet.2022.101530] [Reference Citation Analysis]
4 Jones B, Burade V, Akalestou E, Manchanda Y, Ramchunder Z, Carrat G, Nguyen-Tu MS, Marchetti P, Piemonti L, Leclerc I, Rajamannar T, Vilsboll T, Thorens B, Tomas A, Rutter GA. In vivo and in vitro characterisation of GL0034, a novel long-acting GLP-1 receptor agonist. Diabetes Obes Metab 2022. [PMID: 35676825 DOI: 10.1111/dom.14794] [Reference Citation Analysis]
5 Dawed AY, Mari A, Mcdonald TJ, Li L, Wang S, Hong M, Sharma S, Robertson NR, Mahajan A, Wang X, Walker M, Gough S, ‘t Hart LM, Zhou K, Forgie I, Ruetten H, Pavo I, Bhatnagar P, Jones AG, Pearson ER, DIRECT consortium. Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trials.. [DOI: 10.1101/2022.05.27.22271124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bitsi S, Manchanda Y, Eleid L, Mohamed N, Hansen B, Suba K, Rutter GA, Salem V, Jones B, Tomas A. Divergent acute versus prolonged pharmacological GLP-1R responses in adult beta cell-selective β-arrestin 2 knockout mice.. [DOI: 10.1101/2022.04.21.489075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Fuselier T, Mota de Sa P, Qadir MMF, Xu B, Allard C, Meyers MM, Tiano JP, Yang BS, Gelfanov V, Lindsey SH, Dimarchi RD, Mauvais-Jarvis F. Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes. Cell Rep Med 2022;3:100598. [PMID: 35492248 DOI: 10.1016/j.xcrm.2022.100598] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Grau-Bové C, González-Quilen C, Cantini G, Nardini P, Espina B, Bani D, Terra X, Blay M, Rodríguez-Gallego E, Luconi M, Ardévol A, Pinent M. GLP1 Exerts Paracrine Activity in the Intestinal Lumen of Human Colon. Int J Mol Sci 2022;23:3523. [PMID: 35408884 DOI: 10.3390/ijms23073523] [Reference Citation Analysis]
9 Davies A, Tomas A. Appreciating the potential for GPCR crosstalk with ion channels. Progress in Molecular Biology and Translational Science 2022. [DOI: 10.1016/bs.pmbts.2022.06.013] [Reference Citation Analysis]
10 Roßmann K, Akkaya KC, Poc P, Charbonnier C, Eichhorst J, Gonschior H, Valavalkar A, Wendler N, Cordes T, Dietzek-ivanšić B, Jones B, Lehmann M, Broichhagen J. N -Methyl deuterated rhodamines for protein labelling in sensitive fluorescence microscopy. Chem Sci 2022;13:8605-17. [DOI: 10.1039/d1sc06466e] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ast J, Broichhagen J, Hodson DJ. Reagents and models for detecting endogenous GLP1R and GIPR. EBioMedicine 2021;74:103739. [PMID: 34911028 DOI: 10.1016/j.ebiom.2021.103739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
12 Kakuda S, Suresh P, Li G, London E. Loss of plasma membrane lipid asymmetry can induce ordered domain (raft) formation. J Lipid Res 2021;63:100155. [PMID: 34843684 DOI: 10.1016/j.jlr.2021.100155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Manchanda Y, Ramchunder Z, Shchepinova MM, Rutter GA, Inoue A, Tate EW, Jones B, Tomas A. Expression of mini-G proteins specifically halt cognate GPCR trafficking and intracellular signalling.. [DOI: 10.1101/2021.11.24.469908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Mcglone ER, Ansell TB, Dunsterville C, Song W, Carling D, Tomas A, Bloom SR, Sansom MSP, Tan T, Jones B. Hepatocyte cholesterol content modulates glucagon receptor signalling.. [DOI: 10.1101/2021.10.31.466084] [Reference Citation Analysis]
15 González-Santana A, Estévez-Herrera J, Seward EP, Borges R, Machado JD. Glucagon-like peptide-1 receptor controls exocytosis in chromaffin cells by increasing full-fusion events. Cell Rep 2021;36:109609. [PMID: 34433018 DOI: 10.1016/j.celrep.2021.109609] [Reference Citation Analysis]
16 Marzook A, Chen S, Pickford P, Lucey M, Wang Y, Corrêa IR Jr, Broichhagen J, Hodson DJ, Salem V, Rutter GA, Tan TM, Bloom SR, Tomas A, Jones B. Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1. Biochem Pharmacol 2021;190:114656. [PMID: 34129856 DOI: 10.1016/j.bcp.2021.114656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
17 Wu Q, Chen S, Zhu H, Xu N, Yang Q, Yao W, Gao X. Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects. Eur J Pharmacol 2021;907:174203. [PMID: 34048741 DOI: 10.1016/j.ejphar.2021.174203] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Marzook A, Tomas A, Jones B. The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells. Front Endocrinol (Lausanne) 2021;12:678055. [PMID: 34040588 DOI: 10.3389/fendo.2021.678055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
19 Kunselman JM, Lott J, Puthenveedu MA. Mechanisms of selective G protein-coupled receptor localization and trafficking. Curr Opin Cell Biol 2021;71:158-65. [PMID: 33965654 DOI: 10.1016/j.ceb.2021.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
20 Kakuda S, Suresh P, Li G, London E. LOSS OF PLASMA MEMBRANE LIPID ASYMMETRY CAN INDUCE ORDERED DOMAIN (RAFT) FORMATION.. [DOI: 10.1101/2021.05.03.442484] [Reference Citation Analysis]
21 Pickford P, Lucey M, Rujan RM, McGlone ER, Bitsi S, Ashford FB, Corrêa IR, Hodson DJ, Tomas A, Deganutti G, Reynolds CA, Owen BM, Tan TM, Minnion J, Jones B, Bloom SR. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist. Mol Metab 2021;51:101242. [PMID: 33933675 DOI: 10.1016/j.molmet.2021.101242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Jones B. The therapeutic potential of GLP-1 receptor biased agonism. Br J Pharmacol 2021. [PMID: 33880754 DOI: 10.1111/bph.15497] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
23 Marzook A, Chen S, Pickford P, Lucey M, Wang Y, Corrêa IR, Broichhagen J, Hodson DJ, Salem V, Rutter GA, Tan TM, Bloom SR, Tomas A, Jones B. Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.. [DOI: 10.1101/2021.04.01.438033] [Reference Citation Analysis]
24 Lucey M, Ashik T, Marzook A, Wang Y, Goulding J, Oishi A, Broichhagen J, Hodson DJ, Minnion J, Elani Y, Jockers R, Briddon SJ, Bloom SR, Tomas A, Jones B. Acylation of the incretin peptide exendin-4 directly impacts GLP-1 receptor signalling and trafficking.. [DOI: 10.1101/2021.04.01.438030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
25 Chamberlain LH, Shipston MJ, Gould GW. Regulatory effects of protein S-acylation on insulin secretion and insulin action. Open Biol 2021;11:210017. [PMID: 33784857 DOI: 10.1098/rsob.210017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Pickford P, Lucey M, Rujan R, Mcglone ER, Bitsi S, Ashford F, Corrêa IR, Hodson DJ, Tomas A, Deganutti G, Reynolds CA, Owen BM, Tan TM, Minnion J, Jones B, Bloom SR. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.. [DOI: 10.1101/2021.03.02.433157] [Reference Citation Analysis]
27 Dengler DG, Harikumar KG, Pollari S, Sun Q, Brown BT, Shinoki-Iwaya A, Ardecky R, Miller LJ, Sergienko EA. Discovery of small molecule positive allosteric modulators of the secretin receptor. Biochem Pharmacol 2021;185:114451. [PMID: 33545115 DOI: 10.1016/j.bcp.2021.114451] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
28 Manchanda Y, Bitsi S, Kang Y, Jones B, Tomas A. Spatiotemporal control of GLP-1 receptor activity. Current Opinion in Endocrine and Metabolic Research 2021;16:19-27. [DOI: 10.1016/j.coemr.2020.07.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 14.0] [Reference Citation Analysis]
29 Delobel M, Dalle S. G-protein–coupled receptors controlling pancreatic β-cell functional mass for the treatment of type 2 diabetes. Current Opinion in Endocrine and Metabolic Research 2021;16:113-118. [DOI: 10.1016/j.coemr.2020.09.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Jones B, McGlone ER, Fang Z, Pickford P, Corrêa IR Jr, Oishi A, Jockers R, Inoue A, Kumar S, Görlitz F, Dunsby C, French PMW, Rutter GA, Tan T, Tomas A, Bloom SR. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors. J Biol Chem 2021;296:100133. [PMID: 33268378 DOI: 10.1074/jbc.RA120.016334] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
31 Fang Z, Chen S, Manchanda Y, Bitsi S, Pickford P, David A, Shchepinova MM, Corrêa IR Jr, Hodson DJ, Broichhagen J, Tate EW, Reimann F, Salem V, Rutter GA, Tan T, Bloom SR, Tomas A, Jones B. Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells. Int J Mol Sci 2020;21:E8404. [PMID: 33182425 DOI: 10.3390/ijms21218404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
32 Hodson DJ, Rorsman P. A Variation on the Theme: SGLT2 Inhibition and Glucagon Secretion in Human Islets. Diabetes 2020;69:864-6. [PMID: 32312904 DOI: 10.2337/dbi19-0035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Liu Q, He QT, Lyu X, Yang F, Zhu ZL, Xiao P, Yang Z, Zhang F, Yang ZY, Wang XY, Sun P, Wang QW, Qu CX, Gong Z, Lin JY, Xu Z, Song SL, Huang SM, Guo SC, Han MJ, Zhu KK, Chen X, Kahsai AW, Xiao KH, Kong W, Li FH, Ruan K, Li ZJ, Yu X, Niu XG, Jin CW, Wang J, Sun JP. DeSiphering receptor core-induced and ligand-dependent conformational changes in arrestin via genetic encoded trimethylsilyl 1H-NMR probe. Nat Commun 2020;11:4857. [PMID: 32978402 DOI: 10.1038/s41467-020-18433-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
34 Roßmann K, Akkaya KC, Charbonnier C, Eichhorst J, Jones B, Lehmann M, Broichhagen J. Deuterated rhodamines for protein labelling in nanoscopy.. [DOI: 10.1101/2020.08.17.253880] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Pickford P, Lucey M, Fang Z, Bitsi S, de la Serna JB, Broichhagen J, Hodson DJ, Minnion J, Rutter GA, Bloom SR, Tomas A, Jones B. Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide. Br J Pharmacol 2020;177:3905-23. [PMID: 32436216 DOI: 10.1111/bph.15134] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
36 Gray SM, Xin Y, Ross EC, Chazotte BM, Capozzi ME, El K, Svendsen B, Ravn P, Sloop KW, Tong J, Gromada J, Campbell JE, D'Alessio DA. Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells. J Biol Chem 2020;295:11529-41. [PMID: 32554468 DOI: 10.1074/jbc.RA120.014368] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
37 Jones B, Mcglone ER, Fang Z, Pickford P, Corrêa IR, Oishi A, Jockers R, Inoue A, Kumar S, Görlitz F, Dunsby C, French PM, Rutter GA, Tan T, Tomas A, Bloom SR. Signal bias at glucagon family receptors: rationale and downstream impacts.. [DOI: 10.1101/2020.04.26.062372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Lønsmann I, Bak LK. Potential role of adenylyl cyclase 8 signaling complexes in regulating insulin secretion from pancreatic beta cells. Cell Signal 2020;72:109635. [PMID: 32283257 DOI: 10.1016/j.cellsig.2020.109635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Lucey M, Pickford P, Bitsi S, Minnion J, Ungewiss J, Schoeneberg K, Rutter GA, Bloom SR, Tomas A, Jones B. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. Mol Metab 2020;37:100991. [PMID: 32278079 DOI: 10.1016/j.molmet.2020.100991] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
40 Fang Z, Chen S, Pickford P, Broichhagen J, Hodson DJ, Corrêa IR Jr, Kumar S, Görlitz F, Dunsby C, French PMW, Rutter GA, Tan T, Bloom SR, Tomas A, Jones B. The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists. ACS Pharmacol Transl Sci 2020;3:345-60. [PMID: 32296773 DOI: 10.1021/acsptsci.0c00022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
41 Willard FS, Ho JD, Sloop KW. Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology. Adv Pharmacol 2020;88:173-91. [PMID: 32416867 DOI: 10.1016/bs.apha.2020.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
42 Khan R, Tomas A, Rutter GA. Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide. Peptides 2020;125:170201. [DOI: 10.1016/j.peptides.2019.170201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
43 Fang Z, Chen S, Pickford P, Broichhagen J, Hodson DJ, Corrêa IR, Kumar S, Görlitz F, Dunsby C, French P, Rutter GA, Tan T, Bloom SR, Tomas A, Jones B. The influence of peptide context on signalling and trafficking of glucagon-like peptide-1 receptor biased agonists.. [DOI: 10.1101/2020.02.24.961524] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Lucey M, Pickford P, Minnion J, Ungewiss J, Schoeneberg K, Rutter GA, Bloom SR, Tomas A, Jones B. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists.. [DOI: 10.1101/855874] [Reference Citation Analysis]
45 Pickford P, Lucey M, Fang Z, Bitsi S, Broichhagen J, Hodson DJ, Minnion J, Rutter GA, Bloom SR, Tomas A, Jones B. Differences in signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide.. [DOI: 10.1101/803833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 [DOI: 10.1101/2020.06.24.168260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]